Licensed Practical Nurse in Brick, NJ Accepting Medicare
8 Licensed Practical Nurse nurses found. Showing 1 - 8
 Omegia Radleman, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2775 Hooper Ave, #105, Brick, NJ 08723 Phone: 800-950-6066 |
 Ademuyiwa Adegbite, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1500 Route 88, Brick, NJ 08724 Phone: 732-458-1700 |
Mutahannah Broomes, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 293 Birch Bark Dr, Brick, NJ 08723 Phone: 732-604-6762 |
Dorcas Folasade Ojo, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 503 Brick Blvd Ste 101, Brick, NJ 08723 Phone: 848-333-3853 |
Gutemberg Charles-saint, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1500 Route 88, Brick, NJ 08724 Phone: 732-458-1700 |
Danielle Edelstein, APN-C Licensed Practical Nurse Medicare: Medicare Enrolled Practice Location: 1673 Route 88 W, Brick, NJ 08724 Phone: 732-458-2000 Fax: 732-458-4523 |
Cathleen Guthorn, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 190 16th Ave, Brick, NJ 08724 Phone: 800-950-6066 |
Mrs. Nancy L Canfield, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 108 Taft Dr, Brick, NJ 08724 Phone: 732-295-8126 Fax: 732-295-8127 |
News Archive
Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC
Adolor Corporation today announced the initiation of a Phase 2 proof-of-concept (PoC) study of ADL5945 in patients suffering from opioid-induced constipation (OIC).
New improved model for cancer wasting syndrome cachexia
A new model of cancer-related cachexia promises to help scientists understand why patients with cancer show severe wasting, which in turn may drive the development of better therapies.
Sangart completes enrollment for MP4OX Phase IIa study in severely injured trauma patients
Sangart, Inc., today announced that enrollment was completed in a Phase IIa clinical study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. Complete study results are expected, after follow up of outcomes in these patients, in the second half of 2010.
Ipsen, Active Biotech sign deal to co-develop and commercialize TASQ
Active Biotech AB and Ipsen announced today that they have entered into a broad partnership to co-develop and commercialize Active Biotech's investigational compound Tasquinimod "TASQ".
› Verified 5 days ago